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Abstract
Background: Cardiovascular disease is second only to cancer recurrence as a determinant of lifespan in cancer
survivors, and cancer therapy-related cardiac dysfunction is a clinically important risk factor. We aim to investigate
the use of cardiac magnetic resonance imaging (MRI) to evaluate early tissue changes and perform functional
assessment of chemo- and radiation-induced cardiotoxicity and to identify MRI prognostic indicators of
cardiotoxicity in breast cancer patients.
Methods: A 3-min cardiac imaging protocol will be added to the breast MRI examination to diagnose
cardiotoxicity in breast cancer patients. Standardized MRI-based evaluation of breast cancer and the left ventricular
myocardium will be performed at baseline and at 3, 6, and 12 months and 2 years or more after cancer treatment.
We will analyze both ventricular volume and ejection fraction (EF), strain of left ventricle (LV), native T1, extracellular
volume fraction (ECV), and T2 values acquired in the mid LV.
Discussion: The primary result of this study will be the comparison of the prognostic value of MRI parameters
(native T1, ECV, both ventricular systolic function and LV strain) for cardiotoxicity. The endpoint is defined as the
occurrence of a major adverse cardiac event (MACE). The secondary outcome will be an assessment of the
temporal relationships between contractile dysfunction and microstructural injury over 4 years using MRI. This study
will assess the usefulness of quantitative MRI to diagnose cardiotoxicity and will clarify the temporal relationships
between contractile dysfunction and microstructural injury of the LV myocardium using MRI during breast cancer
treatment.
Trial registration: The protocol was registered at clinicaltrials.gov (Clinical trial no. NCT03301389) on October 4, 2017.
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Background
The side effects of cancer therapy have recently attracted
significant attention [1]. Earlier diagnosis and improved
systemic therapies, including targeted therapies, lead to
longer life expectancy after cancer treatment [2–4].
Treatment-related comorbidities have thus become an
important issue for long-term cancer survivors [5].
Cancer therapy-related cardiac dysfunction (CTRCD)
is the second leading cause of death in cancer survivors
after cancer-related mortality [1, 5, 6]. In particular,
CTRCD is an important problem in the context of breast
cancer because the incidence in young women is in-
creasing while the prognosis is improving due to the de-
velopment of various new treatments. Moreover, various
breast cancer treatments specifically lead to cardiac
dysfunction.
Current guidelines consider left ventricular ejection
fraction (LVEF) assessment using echocardiography as
the standard diagnostic technique for detecting
chemotherapy-induced cardiotoxicity [7, 8]. However,
magnetic resonance imaging (MRI) may play an import-
ant role in cardiac evaluation among cancer patients.
MRI is the gold standard for the evaluation of ventricu-
lar volumes and function, with greater intra- and inter-
observer reproducibility than other modalities, and MRI
may achieve higher sensitivity in identifying cardiomyop-
athy than other diagnostic techniques [8, 9].
The increasingly used T1 mapping sequences im-
proved the usefulness of cardiac MRI, which enables
tissue characterization through quantitative analysis of
phenomena such as myocardial edema, inflammation,
and fibrosis, thus playing an important role in the
diagnosis of early and late cardiotoxicity in cancer pa-
tients [10, 11]. However, the relationship between
contractile dysfunction and microstructural injury is
poorly understood. A previous study based on experi-
ments on animals reported that T1-mapping MRI is
useful for the early diagnosis of chemotherapy-
induced cardiotoxicity [12].
The objective of our proposed study is to investigate
the use of cardiac MRI to evaluate early tissue changes
and perform functional assessment in chemo- and
radiation-induced cardiotoxicity and to identify cardio-
toxicity prognostic factors in patients with breast cancer.
Primary hypothesis
The Cardiac Magnetic Resonance for Early Detection of
Cardiotoxicity in Breast Cancer (CareBest) study hy-
pothesizes that the evaluation of early tissue changes
and functional assessment using cardiac MRI would be
useful in the early detection and risk stratification of
chemotherapy- and radiation therapy-induced cardio-
toxicity in patients with breast cancer.
This hypothesis is supported by the following
considerations
1) In the early phase of exposure to an anthracycline
agent, tissue injury and concurrent elevation of
native T1 and extracellular volume fraction (ECV)
values were noted in the preclinical study, without
significant left ventricular (LV) reduction.
Therefore, T1 mapping MRI allows for earlier
detection of chemotherapy-induced cardiotoxicity
[12]. T1 mapping parameters represent good sur-
veillance markers of tissue injury during the early
phase of cardiotoxicity.
2) Many studies suggest that CTRCD is not a
functional but a structural disorder. The
relationship between contractile dysfunction and
microstructural injury, such as myocyte damage,
fibrosis, and inflammation, remains poorly
understood [11]. It was thus hypothesized that the
evaluation of tissue changes using cardiac MRI
would be more effective for cardiotoxicity risk




CareBest is a single-center, large-scale prospective
study. To achieve the goal of the study, cardiac MRI pro-
tocols for cardiotoxicity diagnosis will be applied to
breast cancer patients who have received or are planning
to receive chemotherapy. A 3-min cardiac imaging
protocol was added to the breast MRI scanning protocol
as a screening tool. The protocol includes T1 and T2
mapping and cine imaging of the LV myocardium. MRI
is performed at 3 months, 6 months, and 2 years after
treatment. Treatment protocols and MRI timing are
shown in Fig. 1.
Primary and secondary objectives
The primary objective of this study is to investigate and
compare the prognostic value of cardiac MRI parameters
(native and postcontrast T1 mapping, ECV, right ven-
tricular (RV), LV systolic function, and global longitu-
dinal strain of LV) for cardiotoxicity. The endpoint is
MACEs.
The secondary objectives are to determine the tem-
poral relationships between contractile dysfunction and
microstructural injury over a four-year period using car-
diac MRI across all patients and by subgroup analysis ac-
cording to treatment (e.g., chemotherapy regimen,
targeted therapy agents, and radiation dose) and to com-
pare the diagnostic accuracy of MRI, echocardiography
or multigated acquisition (MUGA) by subgroup analysis.
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Study population
This prospective study will enroll over 2000 participants
referred for breast cancer evaluation using MRI in a sin-
gle center. All enrolled patients will undergo standard-
ized breast MRI including a cardiac imaging protocol at
the time points specified above and blood analysis to as-
sess hematocrit (Hct) levels immediately before each
MRI examination.
Inclusion criteria
Patients ≥18 years of age are considered eligible if, fol-
lowing the initial oncology consultation, breast cancer is
diagnosed and related therapeutic plans are formulated.
All subjects will agree to participate by giving both ver-
bal and written informed consent. This prospective
study was approved by the institutional review board of
Yonsei University College of Medicine.
Exclusion criteria include prior mammoplasty, history
of other cancers, confirmed benign breast disease, poor
image quality due to uncontrolled breast holding,
arrhythmia, or patients with contraindications to MRI
(i.e., claustrophobia, estimated glomerular filtration rate
(eGFR) < 30).
Cardiac MRI protocol
A standardized breast and cardiac MR examination will
be performed with 3 T MR scanners with an 8-channel
breast coil (GE MRI 750w, GE Healthcare, Milwaukee,
WI, USA). Because breast MRI is performed with the
patient in a prone position, peripheral pulse gating will
be applied for cardiac imaging.
The cardiac protocol includes pre- and postcontrast
T1 mapping, T2 mapping, and cine imaging of both ven-
tricular myocardia. Motion-corrected native T1 and
postcontrast T1 and T2 mapping images will be ac-
quired at the end of diastole in the short axis orientation
of mid LV using a FIESTA-based 3(3)5 MOLLI se-
quence. Post-contrast T1 images will be acquired 15 min
after the bolus injection of the contrast agent (0.1 mmol/
kg body weight of gadolinium-based contrast agent,
Gadobutrol 604.76 mg/ml).
The imaging parameters for the 2D FIESTA cardiac
cine MRI will be set as follows: flip angle = 45°, repeti-
tion time (TR) = 3.0 ms, echo time (TE) = 1.1 ms, field of
view (FOV) = 390 × 390 mm, matrix = 160 × 192, mea-
sured pixel size = 2.4 × 2.0 mm, slice thickness = 8 mm (2
mm gap between adjacent slices), number of slices = 9,
temporal resolution = 60ms, and ASSET factor = 2.
The specific scan parameters for T1 mapping will be
set as follows: flip angle = 35°, TR = 2.8 ms, TE = 0.9 ms,
FOV = 300 × 300mm, matrix = 160 × 128, delay time
(TD) = 220 ms, measured pixel size = 1.9 × 2.3 mm, slice
thickness = 8 mm, and acquisition window = 361ms.
The specific scan parameters for FSE-based black blood
T2 mapping will be set as follows: TR = 1 RR; total echo
train length (ETL) = 16; FOV= 300 × 300mm; matrix =
160 × 128; measured pixel size = 1.9 × 2.3mm; slice thick-
ness = 8mm; 4 echoes with effect TEs = 11.3, 33.9, 56.5, and
79.1ms; acquisition window= 91ms; and ASSET factor = 2.
Sequential short axis cine imaging will be performed
including the entire ventricular myocardium in addition
to standard long-axis views using the 2D FIESTA se-
quence. The specific scan parameters will be set as fol-
lows: flip angle = 45°, TR = 3.0 ms, TE = 1.1 ms, FOV =
390 × 390mm, matrix = 160 × 192, measured pixel size =
2.4 × 2.0 mm, slice thickness = 8 mm (2mm gap between
adjacent slices), number of slices = 9, temporal reso-
lution = 60 ms, and ASSET factor = 2.
Fig. 1 Study design Black circles indicate MRI scanning
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The sequences for breast MR examination include a
three-plane localizing sequence, axial T2-weighted fast-
spin- echo and T2-stimulated inversion recovery (STIR)
sequence, and diffusion-weighted imaging before con-
trast administration. 3D dynamic postcontrast-enhanced
(DCE) images and a T1-weighted 3D delayed postcon-
trast sequence will be acquired in the sagittal plane after
contrast injection.
Native T1 and T2 images will be acquired between
T2-STIR and diffusion images, while postcontrast T1
images will be acquired after delayed postcontrast im-
ages. Cine images will be acquired before dynamic im-
ages. Precontrast T1 and T2 mapping images will be
acquired before DWI imaging, and postcontrast T1
mapping imaging will be performed after dynamic con-
trast imaging. The hematocrit (Hct) levels of the patients
will be acquired on the day of cardiac MRI.
Cardiac MRI analysis
Both ventricular volumes and systolic function
All MR images will be analyzed using cvi42 image ana-
lysis software (Circle Cardiovascular Imaging Inc., Cal-
gary, AB, Canada). Short-axis cine images will be
analyzed using semi-automated contouring of the endo-
cardial and epicardial borders of both ventricles at end-
diastole and end-systole to calculate both ventricular
function (i.e., RV, LV end-diastolic volume (RVEDV,
LVEDV), end-systolic volume (RVESV, LVESV), cardiac
output, stroke volume, RVEF, and LVEF).
T1 and T2 mapping analysis
One native T1, one postcontrast T1, and one T2 map-
ping image acquired on the mid LV will be transferred
to the software. A region of interest (ROI) will be freely
drawn on the septum. Images with severe artifacts will
be coded and removed from the analysis.
Mean segmental native T1, T2, and postcontrast T1
values are calculated for each patient. ECV values are
calculated using the mean values of native and postcon-
trast T1 and hematocrit, as previously established [13].
Myocardial strain analysis
Feature tracking analysis will also be performed using
cvi42 software. The long axis and short-axis cine images
will be loaded onto the software. Endocardial and epicar-
dial borders of the LV in both the long- and short-axis
views were semi-automatically delineated in the end-
diastolic phase. The feature software automatically mea-
sured the global longitudinal strain in the two-
dimensional (2D) longitudinal directions. Analysis of in-




– AC regimen: doxorubicin 60 mg/m2 with
cyclophosphamide (600 mg/m2) IV every 3 weeks for
a total of 4 cycles (cumulative dose of doxorubicin:
240 mg/m2)
– AC followed by taxane: 4 cycles of AC followed by
taxane (paclitaxel 80 mg/m2 IV once a week for 12
weeks, or docetaxel 75 mg/m2 IV every 3 weeks, for
a total of 4 cycles)
– CMF regimen: cyclophosphamide (600 mg/m2) with
methotrexate (60 mg/m2) and fluorouracil (600 mg/
m2) at days 1 and 8 every 4 weeks, for a total of 6
cycles
– TC regimen: docetaxel 75 mg/m2 and
cyclophosphamide 600 mg/m2 IV every 3 weeks for a
total of 4 cycles
HER2-targeted therapy
-HPTC regimen: Trastuzumab 8mg/kg loading dose and
6mg/kg maintenance dose, pertuzumab 840 mg loading
dose and 420 mg maintenance dose, docetaxel 75 mg/
m2, carboplatin every 3 weeks for a total of 6 cycles.
-Trastuzumab: trastuzumab 8mg/kg IV (loading dose)
followed by 6 mg/kg IV (maintenance dose) every 3
weeks for a total of 18 cycles or trastuzumab 600 mg SC
every 3 weeks for a total of 18 cycles for HER2-positive
breast cancer: Trastuzumab will be given after the com-
pletion of the doxorubicin regimen regardless of the tax-
ane regimen.
Clinical outcomes
The primary outcome is MACEs defined as CV death,
hospitalization due to heart failure, and/or heart trans-
plantation. The secondary outcome is left ventricular
dysfunction, defined as a decrease in the LVEF of > 10
percentage points to a value < 53% [9]. The follow-up
duration will be up to 4 years after treatment.
Sample size considerations
There is no generally accepted approach to estimate the
sample size for studies of risk prediction models [14].
We will enroll the largest possible number of patients to
ensure the stability of the prediction model based on
MRI parameters.
Preliminary study
Reliability of cardiac imaging during breast MRI
We will perform a preliminary study to evaluate the
feasibility of cardiac imaging during breast MRI in con-
trol subjects (n = 15). All patients will undergo planned
cardiac imaging with a cardiac coil in a supine position,
without contrast agent. A native T1 cardiac image in a
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short axis plane will be acquired. After cardiac imaging,
the planned breast+cardiac imaging protocol will be per-
formed in a prone position with contrast agent.
Statistical analysis
Categorical baseline characteristics will be expressed as
numbers and percentages, and continuous variables will
be expressed as the means and standard deviations. To
evaluate the prognostic value of T1 mapping parameters
for cardiotoxicity, Cox proportional hazard regression or
other transformations will be used after checking the
proportional hazard assumption. To determine and
compare the prognostic value of native T1 and ECV and
that of LVEF or global longitudinal strain of LV, time-
dependent ROC curves, Harrell’s C statistic and boot-
strapping with 1000 repetitions will be used. A linear
mixed model will be used to evaluate the temporal rela-
tionship between LVEF, native T1, ECV, and T2 values.
The diagnostic accuracies of MRI, MUGA, and echocar-
diography for cardiotoxicity will be evaluated by ROC
curves, and the significance of the differences among the
related areas under the curves (AUC) will be evaluated
using Delong’s method [15]. P-values less than 0.05 will
be considered statistically significant. All statistical ana-
lyses will be performed using SAS (version 9.4, SAS In-
stitute Inc., Cary, NC, USA).
Study approval and progression
The study protocol was approved by the regional institu-
tional review board in October 2016 (IRB No. 4–2016-
0730), and the protocol is registered at clinicaltrials.gov
(Clinical trial no. NCT03301389). A data and safety
monitoring board was constituted to ensure the safe
continuation of the study.
Discussion
This prospective study will be the largest study investi-
gating serial MRI-based evaluation of CTRCD. We will
investigate the effects of chemotherapy, radiation ther-
apy, and other therapies on myocardial function and
structure, thus providing additional evidence on whether
cardiac MRI is the optimal screening tool for the diagno-
sis of chemo or radiation therapy-induced cardiotoxicity,
given its advantages in terms of quantitative assessment.
Recently, significant attention has been focused on the
field of cardio-oncology. Many influential clinical guide-
lines for cardiovascular toxicity have been developed [8,
10, 16–19]. The current diagnostic criteria are based on
left ventricular functional changes [17]. However,
chemotherapy-induced cardiotoxicity is considered a
continuum that begins with subclinical myocardial cell
injury, leading to an early, asymptomatic decline in
LVEF, which can eventually develop into symptomatic
heart failure [12, 20]. LVEF can be used to detect
myocardial damage only after functional impairment has
already occurred.
Cardiac MRI is the gold standard for the evaluation of
ventricular volumes and function, with greater intra-
and inter-observer reproducibility than other methods,
and quantitative cardiac MRI may play an important role
in the cardiac evaluation and risk stratifications of can-
cer patients [11, 21]. Recently, many papers have been
published that show the usefulness of MRI-obtained pa-
rameters such as ventricular volume, function, mass, and
strain in diagnosing CTRCD [11, 22–26]. The most im-
portant capability of MRI is tissue characterization with
quantitative MR parameters. Tissue characterization by
cardiac MRI can help identify early myocardial injuries
that are not included in the current diagnostic criteria
[11, 21, 27].
Breast cancer therapy involves many adjuvant therap-
ies in addition to surgery, most of which cause heart-
related problems. Anthracycline, used as a primary
chemotherapy agent in breast cancer, is a well-known
cardiotoxic agent [8, 28], with the incidence of cardio-
toxicity ranging from 4 to > 36% in patients receiving
500–550mg/m2.
Other conventional chemotherapy agents used in
breast cancer treatment, including cyclophosphamide
and taxanes, also induce myocardial dysfunction [8]. The
recently adopted targeted therapy agent trastuzumab,
which improves outcomes of patients with HER2-
positive breast cancer, is also notoriously associated with
treatment-related cardiotoxicity [8].
Radiation therapy, another major treatment for breast
cancer, induces myocardial fibrosis, microcirculatory in-
jury, and myocardial infarction. High-dose radiation ex-
posure is used on the thorax in the adjuvant setting after
breast surgery [29].
Therefore, cardiac evaluation during breast cancer
treatment is clinically very important. This study is
based on the observation that it is very efficient to per-
form an additional myocardium examination during the
routine surveillance of breast cancer. Indeed, the separ-
ate assessment of cardiac function using echocardiog-
raphy or MUGA on a regular basis during surveillance
of breast cancer treatment is somewhat cumbersome.
Moreover, serial MUGA evaluations may cause signifi-
cant radiation exposure. For these reasons, we set up a
short-term imaging protocol for the evaluation of myo-
cardial tissue and myocardial dysfunction, and we tested
the feasibility of cardiac imaging using a breast coil in
the preliminary study.
The limitation of this study is that it is a single-center
prospective registry study. Although blood biomarkers
such as NT proBNP or troponins have been demon-
strated to be good early markers of cardiotoxicity, they
are not included in the study protocol.
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In conclusion, the simultaneous evaluation of breast
cancer and cardiac function during treatment can poten-
tially be very effective in terms of cost and time. More-
over, it may help the early detection of cardiotoxicity
during cancer therapy, while quantitative imaging
methods may provide additional value for the surveil-
lance of patients at risk of CTRCD.
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